New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk’s OZEMPIC Approval Heat Up the Chronic Kidney Disease Therapeutic Market | DelveInsight The FDA’s recent approval of OZEMPIC ...
Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...
New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk's OZEMPIC Approval Heat Up the Chronic Kidney disease Therapeutic market | DelveInsight The FDA's recent approval of OZEMPIC ...
Novo Nordisk launched "My Ozempic® Era" today, a national campaign which spotlights the longstanding Ozempic® patient ...
New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk’s OZEMPIC Approval Heat Up the Chronic Kidney Disease Therapeutic Market | DelveInsight The FDA’s recent approval of OZEMPIC highlights ...
FDA drug alerts in endocrinology, including drug approvals, drug warnings, FDA medical device recalls, and FDA drug label ...
Hosted on MSN29d
FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patientsabout a third of adults with diabetes also have chronic kidney disease, according to the U.S. Centers for Disease Control and Prevention The clinical trial tested the efficacy of Ozempic when ...
Recent research throws into question whether GLP-1 drugs increase the risk of certain types of thyroid cancer.
1don MSN
Weight loss drugs like Ozempic deliver more health benefits than expected.
Kennedy Jr., who was tapped to lead the Department of Health and Human Services for the Trump administration, recently ...
Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...
With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback